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OPINION Liver transplantation: immunosuppression and
oncology
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a, and
Andrew K. Burroughs
b,c
Purpose of review
Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and
recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Recent findings
There is accumulating evidence linking increased exposure to immunosuppressants and carcinogenesis,
particularly concerning calcineurin inhibitors (CNIs), azathioprine and antilymphocyte agents. A recent
study including 219 HCC transplanted patients showed that HCC recurrence rates were halved if a
minimization of CNIs was applied within the first month after liver transplant. With mammalian target of
rapamycin (mTOR) inhibitors as approved immunosuppressants for liver transplant patients, pooled data
from several retrospective studies have suggested their possible benefit for reducing HCC recurrence.
Summary
Randomized controlled trials with sufficiently long follow-up are needed to evaluate the influence of
different immunosuppression protocols in preventing malignancy after LT. Currently, early minimization of
CNIs with or without mTOR inhibitors or mycophenolate seems a rational strategy for patients with risk
factors for de-novo malignancy or recurrence of HCC after liver transplant. A deeper understanding of the
immunological pathways of rejection and cancer would allow for designing more specific and safer drugs,
and thus to prevent cancer after liver transplant.
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INTRODUCTION
Theimprovementinsurgicaltechniquesandmedical
care has prolonged survival after liver transplan-
tation, leading to a parallel increase of long-term
complications such as de-novo malignancy, which
is becoming a major source of morbidity and
mortality [1
&]. Several population-based studies
worldwide have reported a two- to three-fold
increased cancer rates in liver transplant patients,
when compared with age and sex-matched popu-
lations [2–12]. Moreover, in patients transplanted
withhepatocellularcarcinoma(HCC),tumourrecur-
rence affects 15–20% of patients despite a careful
selection of candidates based on the Milan criteria
[13], and therapeutic options are very limited in this
situation. In a recentanalysis of 93634 patients from
theEuropeanLiverTransplantRegistry(1968–2009),
21% of deaths occurred because of de-novo tumours
or recurrence of HCC, demonstrating the critical
importance of these complications in the current
liver transplantation scenario [14].
The link between immunosuppression and
oncogenesis is well established, as the integrity of
the immune system is one of the defenses against
cancer [15]. In the initial stages of carcinogenesis,
several components of the immune system are able
to locate and destroy cancer cells, delay tumour
progression and prevent vascular invasion and
metastasis. The immune system also allows for
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control of viral infections related to cancer. Animal
models with defective function of natural killer cells
and/or T cells (CD8
þ cytotoxic or CD4
þ T helper)
have increased risk and aggressiveness of tumours,
suggesting a cumulative cancer promoting effect,
when both the innate and the adaptive immune
pathways are impaired [16]. Conversely, cancer cells
from highly aggressive tumours are able to paralyze
infiltrating immune cells by secreting immunosup-
pressive molecules such as transforming growth
factor (TGF)-b and CCL21 [17,18]. Indeed the types
of cancer with the highest standardized incidence
ratio after liver transplantation are related to infec-
tions (Kaposi sarcoma, nasopharyngeal carcinoma,
cervical and vulvar cancer) [19], have an origin in
the immune system (lymphoproliferative disorders
particularly Burkitt lymphoma [20]), or are located
in exposed areas (skin cancer, head and neck cancer)
(Table 1) [2,3,5–8,10–12]. Thus, the increased risk
of overall malignancy after liver transplantation is
partly related to these otherwise less frequent
tumours, leading to a specific ‘cancer pattern’
related to immunosuppression. It is not surprising
that this ‘cancer pattern’ is reproduced in AIDS
wherein effective antiretroviral therapies have
prolonged survival [21], and establish a chronic
immunosuppressive status [22,23]. New therapies
that enhance the immune system are becoming a
reality inthemanagement ofseveraltypesof cancer.
However, there are few studies evaluating
immunosuppression protocols to prevent or reduce
malignancy after liver transplantation, and they
have a poor level of evidence (Fig. 1). There are
no randomized controlled trials powered to detect
differences in de-novo tumours or recurrence of
HCC, mainly because of the heterogeneity in the
biology of different types of cancer, and the
prolonged follow-up required. The available evi-
dence comes from observational studies, and thus
results should be interpreted with caution because
of the great variability in clinical practice between
livertransplantinstitutions,whichincreasestherisk
of bias when analyzing multicentre pooled data.
Despite this situation, the general behaviour among
clinicians is to minimize the exposure to immuno-
suppressants as much as possible after liver trans-
plantation. With these background caveats, we
present a comprehensive review of the available evi-
dence about the relationship between the immuno-
suppressive drugs most frequently used in liver
transplant patients and the risk of malignancy.
We conclude with some recommendations to
prevent de-novo malignancy and recurrence of
HCC after liver transplantation.
CALCINEURIN INHIBITORS
Calcineurin inhibitors (CNIs) are the mainstay of
immunosuppression after liver transplantation.
Tacrolimus is the most frequently used because of
reduced acute rejection rates and better graft and
patient survival, compared with cyclosporine [24].
In-vitro studies and animal models have shown
that both tacrolimus and cyclosporine are able to
activate proto-oncogenes and pathways of cancer
such as TGF-b in a dose-dependent fashion, thus
promoting tumour proliferation, resistance to
apoptosis and metastasis [25–27].
The risk of malignancy with tacrolimus or
cyclosporine should be similar in clinical practice.
To our knowledge, only one single-centre study
has described an increased risk of malignancy in
liver transplant patients treated with cyclosporine
compared with tacrolimus [28]. However, the
authors admit that a different monitoring was used
for cyclosporine, and lower rejection rates were
detected in this group, suggesting higher immuno-
suppressive potency with cyclosporine than with
tacrolimus in this series. The only randomized
controlled trial aiming to detect differences in
de-novo malignancy compared two regimens with
cyclosporine in kidney transplant recipients:
conventional trough levels (i.e. 150–250ng/ml)
vs. reduced trough levels (i.e. 75–125ng/ml). The
group with conventional exposure had increased
rates of de-novo tumours (32 vs. 19%; P¼0.03)
[29]. Thus, the risk of malignancy related to CNI
in clinical practice may comefrom the dosage rather
than the type of CNI used.
Several retrospective studies have shown a dose-
dependent relationship between CNI and recurrence
of HCC after liver transplantation [30,31,32
&&]. The
over-exposure to CNI may be particularly relevant
KEY POINTS
  De-novo malignancy after liver transplantation has
become a major source of morbidity and mortality.
  The immunosuppression plays a central role in the
increased risk of cancer after liver transplantation,
including recurrence of hepatocellular carcinoma.
  CNIs, azathioprine and antithymocyte globulins have a
pro-oncogenic effect, whereas mTOR inhibitors
(everolimus and sirolimus) and mycophenolate seem to
be protective against cancer.
  An early minimization of CNIs should be universally
applied after liver transplantation and for selected
patients with increased risk of rejection, the addition of
either mTOR inhibitors or mycophenolate would be the
most rational approach to prevent malignancy.
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early after liver transplantation when the immune
system should be able to detect and destroy remain-
ing HCC cells in the bloodstream. Indeed, an obser-
vational study with 219 patients transplanted with
HCCshowedthatthosepatientshavingmeantrough
concentrationsmorethan10ng/mlfortacrolimusor
morethan300ng/mlforcyclosporinewithinthefirst
30days afterliver transplantation hadnearlya three-
fold increased risk of HCC recurrence, after control-
ling for possible confounding factors [32
&&]. More-
over, tacrolimus trough concentrations 7–10ng/ml
within the first 30 days after liver transplantation
result in similar rejection rates [33
&], halved renal
impairment[33
&]andlongergraftsurvival[34],when
compared with trough concentrations more than
10ng/ml, which is the ‘conventional’ exposure in
randomized trials [35]. Therefore, tacrolimus trough
concentrations7–10ng/mlshouldbethestandardof
care within the first month after liver transplan-
tation, and future randomized trials should imple-
ment reduced tacrolimus trough concentrations in
their design.
MTOR INHIBITORS
The mammalian target of rapamycin (mTOR) is a
serine/threonine kinase involved in cellular growth,
proliferation, metabolism and angiogenesis, and it
comprises two signalling pathways: mTOR complex
1, responsible for cellular growth and proliferation
in response to immune regulatory signals, and
mTOR complex 2 involved in aspects of cell meta-
bolism [36
&]. There are two mTOR inhibitors avail-
able for liver transplant patients. Sirolimus is a non-
selective inhibitor of mTOR complexes 1 and 2, and
everolimus has a restricted effect on mTOR complex
1. Both drugs have shown immunosuppressive and
anticancer properties in animal models including
HCC [37–40].
In liver transplantation, the mTOR inhibitors
are used mainly as renal sparing agents, owing to
a potent immunosuppressive effect, which allows
reduction of CNI exposure, or even for a conversion
from a CNI based to a mTOR inhibitor-based regi-
men [41,42]. There are no published randomized
controlled trials evaluating the effect of mTOR
inhibitors in preventing de-novo malignancy or
recurrence of HCC after LT. The available evidence
is based on clinical reports and retrospective studies,
thus making it difficult to extract solid conclusions.
Despitethis,manytransplantcentresfrequentlyadd
or convert to a mTOR inhibitor when there are risk
factors for malignancy after liver transplantation, or
even when a tumour has been diagnosed. There are
several reports of improved outcome of lymphopro-
liferative disorders and Kaposi sarcoma after switch-
ing to a mTOR inhibitor [43].
Regarding prevention of HCC recurrence, there
are five retrospective studies evaluating the role
of sirolimus-based immunosuppression after liver
Randomized
trial
Calcineurin
inhibitors
MTOR
inhibitors
Mycophenolate
Azathioprine
Steroids
Anti-ILR2
Anti-thymocyte
globulin
Calcineurin
inhibitors
MTOR
inhibitors
Mycophenolate
Azathioprine
Steroids
Anti-ILR2
Anti-thymocyte
globulin
Randomized
trial
Clinical
prospective
Clinical
prospective
Clinical
retrospective
Clinical
retrospective Experimental Experimental
Anti-oncogenic effect Pro-oncogenic effect
FIGURE 1. Summary of the level of evidence regarding the influence of the most frequently used immunosuppressive drugs
after liver transplantation and the risk of malignancy (including lymphoproliferative disorders, any type of solid malignancy
and recurrence of hepatocellular carcinoma). The figure points out the scarce number of studies available and the reduced
level of evidence.
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transplantation [44–48], the results of which have
been summarized in two meta-analyses [49
&,50
&].
The conclusions from both are similar suggesting
a protective effect of sirolimus against HCC recur-
rence with an odds ratio (OR) ranging from 0.30
[(95% confidence interval (CI) 0.16–0.55 to 0.42
(95% CI 0.21–0.83), and also a benefit in 5-year
overall survival with OR from 0.35 (95% CI 0.20–
0.61) to 0.40 (95% CI 0.28–0.58). However an
analysis of 26414 patients from the Scientific
Registry of Transplant Recipients Database (USA)
showed an increased risk of all-cause mortality in
patients with hepatitis C treated with sirolimus
(hazard ratio¼1.29; 95% CI 1.08–1.55) [51]. The
limitations of these studies are evident: observatio-
nal and retrospective design, some based on regis-
tries originally designed for a different purpose,
and a high risk of reporting bias. The ongoing
SiLVER study, which is a multicentre randomized
controlled trial evaluating the role of sirolimus in
HCC transplanted patients, may determine the true
effect of mTOR inhibitors in preventing tumour
recurrence, but the results will not be available
before 2016 [52].
With respect to everolimus, there are no clinical
studies suggesting a significant protective effect
against HCC recurrence or de-novo malignancy
after liver transplantation. Aseverolimus has a selec-
tive inhibition on mTOR complex 1, a more specific
antitumour effect would be expected [37], and an
improved metabolic profile has been hypothesized
[53]. However, the activation of feedback signals
makes prediction of the consequences difficult in
clinical practice. The selective blocking of mTOR
complex 1 with everolimus on the severity of
hepatitis C recurrence and graft loss also deserves
further investigation.
ANTIMETABOLITES
The antimetabolites interfere with de novo synthesis
of nucleotides, and herein have a potent cytostatic
effect on lymphocytes, which is more pronounced
than in other cell types. Mycophenolate is the most
widely used after liver transplantation, mainly in
combination with CNI as a renal sparing agent
[54,55]. To date there is no evidence suggesting a
link between the use of mycophenolate and de novo
malignancy after liver transplantation, even in the
long term. A large observational study included
6751 renal transplant patients who received myco-
phenolate from the United Network for Organ Shar-
ing (UNOS) and the collaborative transplant study
registries. There was no significant increase in either
lymphoma or any malignancy when compared with
a matched cohort without mycophenolate. In the
subgroup from the collaborative transplant study,
a longer time to malignancy was found for
mycophenolate-treated patients (log rank 0.026)
[56]. In 3895 heart transplant patients, the use of
mycophenolate had a protective effect against
de-novo malignancy (relative risk¼0.75; 95% CI
0.56–0.95) [57]. The studies evaluating the role of
immunosuppression on HCC recurrence showed no
influence of mycophenolate [31,32
&&].
Azathioprine used as 1mg/kg/day is preferred in
some institutions for patients transplanted with
hepatitis C because of a slower fibrosis progression
and reduced risk of decompensation of severe recur-
rent disease, as recently shown in a randomized
controlled trial with a median follow-up of 8 years
and with protocol biopsies [58]. The prolonged use
of azathioprine has been associated with an
increased risk of nonmelanoma skin cancer, which
may be explained by a dual mechanism, including
an increased DNA damage powered by the inter-
action between ultraviolet-A radiation and 6-thio-
guanine, and an impaired DNA repair system
[59,60]. The actual implication of nonmelanoma
skin cancer, which usually is diagnosed at early
stages, on prognosis is a matter of debate [61,62].
In inflammatory bowel disease patients treated with
azathioprine, there is a four- to five-fold increased
risk of lymphoproliferative disorders, especially in
elderlypatients,butstilllymphomaisaveryuncom-
mon malignancy [63]. However, these data are
hardly transferred to the liver transplant popu-
lation, as doses of azathioprine are at least twice
in patients with inflammatory bowel disease. The
risk of Burkitt lymphoma is increased in liver trans-
plantation patients compared with renal recipients
according to a large registry from the USA, and
azathioprine appeared as an independent risk factor
in this cohort [20]. In liver transplantation patients,
Benlloch et al. [64] retrospectively analyzed a single-
institution experience (n¼772) on the develop-
ment of non-skin malignancy and the risk factors
involved. They found azathioprine as an independ-
ent predictor of any tumour development after
liver transplantation (OR¼3.8; 95% CI 1.7–8.6;
P¼0.004).
OTHER IMMUNOSUPPRESSIVES
Corticosteroids form part of most immunosuppres-
sion protocols within the first months after liver
transplantation. The heterogeneity in dosage and
tapering schedule between institutions makes it
difficult to obtain a reliable analysis of pooled data
[65],andthereisnoevidencesuggestingthattheuse
of corticosteroids influences de novo malignancy
after liver transplantation. In a single registry-based
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study, the use of corticosteroids was protective
against Burkitt lymphoma [20].
The interleukin-2 receptor blockers (basiliximab
and daclizumab – the latter has been withdrawn
from the market) are frequently used immediately
after liver transplantation as induction immuno-
suppression agents in order to delay the introduc-
tion of CNI as part of a renal-sparing strategy [66].
A large observational study with 929 renal trans-
plant patients was unable to find any relationship
between the use of anti-interleukin-2 receptors and
de-novo malignancy. However, induction with
anti-thymocyte globulins, which are polyclonal
antibodies directed against multiple T- and B-cell
antigens responsible for a depletion of peripheral
lymphocytes, is associated with an increased risk for
lymphoma after renal transplantation (0.67 vs.
0.43% with no induction; P¼0.002), whereas basi-
liximab was not (0.38 vs. 0.43% with no induction;
P¼0.33) [67]. However, studies in liver transplant
population are lacking.
FUTURE PERSPECTIVES
The reduced clinical significance of acute cellular
rejection after liver transplantation, which pro-
gresses to chronic rejection and graft loss in less
than 5% of patients, together with the increasing
risk of renal impairment, infections and malig-
nancy, demonstrates that liver transplant patients
have been, and are still, over-immunosuppressed in
many transplant centres [33
&,68]. There are still
recent randomized trials using quadruple immuno-
suppression as a standard of care for liver trans-
plantation patients [69], leading to unnecessarily
reduced rejection rates, a more severe recurrence
of hepatitis C, more frequent infections and new-
onsetdiabetes[70].Acertaingradeofacuterejection
early after liver transplantation provides a benefit in
terms of long-term survival [34,71], and it has been
hypothesized that a complete suppression of acute
rejection may prevent operational tolerance, and
therefore it is neither necessary nor appropriate
[71,72].
The current immunosuppression protocols in
liver transplantation interfere with the immune
system at many different levels simultaneously,
impairing both the innate and the adaptative
immune responses. A better understanding of the
mechanisms underlying rejection is needed to
develop more specific drugs, able to target selective
rejection effectors, while keeping the ability to fight
cancer cells, infections and to develop tolerance. In
the future, a tailored ‘cocktail’ of monoclonal anti-
bodies against specific cytokines, receptors and
growth factors depending on individual patient’s
immunological features will form the standard of
care to prevent chronic rejection and graft loss. The
therapeutic paradigm will change from immuno-
suppression to immunomodulation [73]. With the
available immunosuppressants, the best approach
to prevent malignancy after liver transplantation
nowadays would be to decrease the number and
the dosage of the immunosuppressive drugs to the
minimum, starting as soon as possible after liver
transplantation. A certain grade of immune
response is desirable to prevent cancer, as it is to
facilitate long-term graft tolerance. A single episode
of acute rejection early after liver transplantation is
easily managed and derived mortality is zero,
whereas a single cancer forms a life-threatening
condition with very limited therapeutic options.
CONCLUSION
The studies linking immunosuppression and cancer
afterliver transplantationhave serious biases,which
weaken the evidence: heterogeneity of immunosup-
pression protocols between centres, variable bio-
logic tumour behaviour and inadequate follow-up.
Future studies if these biases are removed will have
a problem of increased follow-up costs. However,
the evidence taken as a whole suggests that the
immunosuppression regimen plays a central role
in de-novo malignancy and in the recurrence of
HCC after liver transplantation. The minimization
of CNI should be universally applied, beginning as
soon as possible after liver transplantation. In
selected patients requiring a more potent immuno-
suppression, the addition of either mTOR inhibitors
or mycophenolate would be the most rational
approach. Prospective studies and randomized con-
trolled trials with a large number of patients and
sufficiently long follow-up are urgently needed to
support the recommendations given, and to explore
the best ‘anti-tumour’ immunosuppression regi-
men.Thenextsteps shouldbeto identify thecritical
nodes in the physiopathology of rejection, and to
develop more specific drugs with a better safety
profile including reduced pro-oncogenic effects.
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